-
Target
Double Helix Biotechnology Development Limited
-
Our Role
Advisor to seller
-
Seller and Location
Double Helix Biotechnology Development Limited, United Kingdom
-
Activity
A leading global provider of market research and market access services to the pharmaceutical and medical device industries
-
Acquiror / Investors and Location
Interpublic Group [NYSE; IPG], United States
-
Activity
One of the world’s leading marketing communications agency networks quoted on the New York Stock Exchange
-
Description of Transaction
Advised the shareholders of Double Helix, a leading provider of market research and market access services with offices in London, New York and Singapore. Generated competitive interest from international buyers from both the media and healthcare sectors and achieved a sale to IPG for its McCann Health division, securing a premium value for the shareholders. This move will enable the business to accelerate its growth internationally.
